Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
3
users have commented on this narrative
46
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
0
users have commented on this narrative
17
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
17
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Rockwell Medical
AN
AnalystHighTarget
Consensus Narrative from 2 Analysts
Aging And Home Care Trends Will Raise Demand Amid Risks
Key Takeaways Strong customer diversification, expanding industry contracts, and competitive gains are poised to drive above-expected revenue growth and significant margin expansion. Leading market position and scalable logistics infrastructure position Rockwell to benefit from industry shifts and unlock recurring, higher-margin future revenue streams.
View narrative
US$5.00
FV
79.6% undervalued
intrinsic discount
-13.25%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Clearside Biomedical
AN
AnalystHighTarget
Consensus Narrative from 4 Analysts
Aging Global Population Will Boost Ocular Treatment Adoption
Key Takeaways Leading drug delivery technology, strong clinical results, and global partnerships could drive rapid adoption, robust licensing income, and significant revenue and margin expansion. Diversified pipeline and growing disease prevalence ensure long-term product launches, revenue diversification, and strong potential for transformative partnerships with next-generation therapy developers.
View narrative
US$6.00
FV
93.0% undervalued
intrinsic discount
112.52%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Hyperfine
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Global Aging And Telemedicine Will Drive Portable MRI Adoption
Key Takeaways Rapid clinical adoption, global expansion, and unique use-cases position Swoop for outsized revenue growth and transformative market share gains over traditional MRI. Strong network effects, recurring high-margin revenue, and scalable operations suggest substantial improvement in operating margins and long-term profitability.
View narrative
US$1.50
FV
7.3% undervalued
intrinsic discount
25.90%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Cibus
AN
AnalystHighTarget
Consensus Narrative from 4 Analysts
Gene Editing And Climate Resilience Will Redefine Crop Development
Key Takeaways Near-global regulatory harmonization and RTDS platform adoption could rapidly accelerate Cibus' market reach, platform dominance, and recurring margin expansion beyond current analyst expectations. Diversification into sustainable ingredients and gene-editing positions Cibus for strong, stable growth through new high-value partnerships and above-industry-average royalty revenues.
View narrative
US$25.00
FV
94.4% undervalued
intrinsic discount
230.89%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
LARK Distilling
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Global Premiumization And Destination Tourism Will Spark Lasting Demand
Key Takeaways Transformational brand repositioning, global expansion, and deep inventory could unlock outsized growth and premium brand equity ahead of market expectations. Experiential tourism and innovative product development are poised to drive high-margin direct sales and lasting appeal among younger consumers.
View narrative
AU$3.30
FV
76.8% undervalued
intrinsic discount
35.22%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Offerpad Solutions
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Digital Transformation And Urbanization Will Boost Online Home Transactions
Key Takeaways Scalable, tech-driven offerings and a seamless hybrid model position Offerpad for accelerated revenue growth and industry-leading margin expansion as digital adoption in real estate rises. Cross-sell opportunities and enhanced liquidity enable Offerpad to capture a larger share of the transaction value chain and pursue aggressive market expansion with reduced risk.
View narrative
US$1.40
FV
2.1% overvalued
intrinsic discount
33.34%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Rani Therapeutics Holdings
AN
AnalystHighTarget
Consensus Narrative from 4 Analysts
Needle-Free Oral Biologics Will Serve Aging Global Demand
Key Takeaways Rani's oral therapy platform offers a significant adoption advantage and margin potential due to its non-invasive delivery and superior performance versus injections. Advancements in manufacturing and partnerships position the company for strong long-term growth while reducing reliance on dilutive financing.
View narrative
US$12.00
FV
95.4% undervalued
intrinsic discount
283.34%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Mersana Therapeutics
AN
AnalystHighTarget
Consensus Narrative from 7 Analysts
Precision Medicine And Global Aging Will Open Opportunities
Key Takeaways Emi-Le's broader therapeutic potential, enhanced dosing strategies, and demographic trends position Mersana for outsized growth and margin expansion in breast cancer markets. Strategic collaborations and proprietary ADC platforms diversify revenue, reduce cash burn, and support long-term growth in precision medicine.
View narrative
US$250.00
FV
97.1% undervalued
intrinsic discount
-4.76%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Organon
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
New Product Launches And Biosimilars Will Open Global Healthcare Markets
Key Takeaways New product launches and biosimilars adoption are driving market share growth, while portfolio shifts and operational efficiencies support stronger margins. Expanding presence in global and emerging markets, together with improving financial flexibility, positions the company for sustained revenue growth and strategic investments.
View narrative
US$13.17
FV
28.3% undervalued
intrinsic discount
1.17%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
27
users have followed this narrative
4 days ago
author updated this narrative
Value any company in seconds
Popular companies